DENVER, CO / January 19, 2016 / CannLabs, Inc. (OTC: CANL), a provider of proprietary, cloud-based analytics and scientific testing methodologies relating to cannabis, has engaged Viridian Capital Advisors to explore strategic alternatives in order to maximize shareholder value.
Mr. Mark Mirken, CannLabs CEO, commented, "The laboratory testing market for cannabis is in its early stages of development, and CannLabs has created one of the foremost brands and intellectual property portfolios in the industry. At this stage in our company's evolution we think it is the right time to engage an advisor to help us explore the best strategic options for our shareholders. This is why we chose to engage Viridian Capital Advisors who, in our opinion, are true thought leaders in the cannabis industry. We have engaged Viridian to enable us to evaluate the alternatives which will become available to us and best fit our short and long term goals."
Mr. Scott Greiper, President and Founder of Viridian Capital Advisors, stated, "Laboratory testing is one of the vital platform technologies in the cannabis marketplace, and must become standardized, consistent and robust in order to maintain the long term health of the cannabis industry. CannLabs proprietary testing methods and significant database of testing data is a valuable asset for legalized U.S. states and foreign countries, and the commercial dispensaries/grows in these regions. Additionally, through its wholly owned subsidiary Experentia Labs, CannLabs' testing laboratories provides hemp testing for both a domestic and international client base."
About CannLabs, Inc.
CannLabs, Inc., is a respected authority and advisor to commercial, governmental and educational entities focused on the Cannabis industry. The company leverages its propriety scientific, testing processes, cloud-based business intelligence and data/analytics as well as consulting services to garner revenues from legalized Cannabis states and their constituents.
Through Carbon Bond Holdings Inc. and the state certified labs it has relationships with, CannLabs delivers best practices around products, services and business intelligence focused on the Cannabis industry. CannLabs customers include states that currently have legalized medical or recreational Cannabis along with their associated growers, dispensaries, manufacturers of edibles, and residential consumers seeking information on cannabis.
For more information, please visit http://www.cannlabs.com.
About Viridian Capital Advisors, LLC
Viridian Capital Advisors, LLC is a financial and strategic advisory firm dedicated to the Cannabis market. Our banking practice, through broker-dealer Pickwick Capital Partners, provides capital and M&A to fund the growth of our clients, while our advisory practice helps to position and build their business. Leveraging our team's decades of high level operating and transactional experience on Wall Street, in industry and in the government, we provide flexible comprehensive strategic and financial solutions that assist cannabis enterprises in realizing their full potential.
For more information, please visit http://www.viridianca.com.
The statements in this press release constitute forward-looking statements within the meaning of federal securities laws. Such statements are based on our current beliefs and expectations and are inherently subject to significant business, economic, and competitive uncertainties and contingencies, many of which are beyond our control. In addition, such forward-looking statements are subject to assumptions with respect to future business strategies and decisions that are subject to change. Potential risks and uncertainties include, but are not limited to, technical advances in the industry as well as political and economic conditions present within the industry. We do not take any obligation to update any forward-looking statement to reflect events or developments after a forward-looking statement was made.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer